Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PEG-modified/site-mutated IL-2 SHR-1916

A polyethylene glycol (PEG)-modified and site-mutated form of the cytokine interleukin-2 (IL-2), with potential immunopotentiating and antineoplastic activities. Upon administration, PEG-modified/site-mutated IL-2 SHR-1916 activates the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway. This induces the selective proliferation of CD8+ T cells and natural killer (NK) cells, enhances tumor cell killing and decreases tumor cell proliferation. Pegylation of IL-2 protects the cytokine from degradation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	IL-2 derivative SHR-1916 PEG-modified/site-mutated interleukin-2 SHR-1916
Code name:	SHR 1916 SHR-1916 SHR1916

PEG-modified/site-mutated IL-2 SHR-1916

Search NCI's Drug Dictionary